Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 3
1988 1
1989 3
1990 2
1991 2
1993 2
1994 1
1995 1
1996 1
1997 2
1998 6
1999 1
2000 5
2001 3
2002 4
2003 4
2004 5
2005 7
2006 1
2007 4
2008 6
2009 5
2010 2
2011 5
2012 7
2013 8
2014 3
2017 4
2018 4
2019 8
2020 4
2021 3
Text availability
Article attribute
Article type
Publication date

Search Results

108 results
Results by year
Filters applied: . Clear all
Page 1
Human PI3Kγ deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology.
Takeda AJ, Maher TJ, Zhang Y, Lanahan SM, Bucklin ML, Compton SR, Tyler PM, Comrie WA, Matsuda M, Olivier KN, Pittaluga S, McElwee JJ, Long Priel DA, Kuhns DB, Williams RL, Mustillo PJ, Wymann MP, Koneti Rao V, Lucas CL. Takeda AJ, et al. Among authors: wymann mp. Nat Commun. 2019 Sep 25;10(1):4364. doi: 10.1038/s41467-019-12311-5. Nat Commun. 2019. PMID: 31554793 Free PMC article.
Lipid signalling in disease.
Wymann MP, Schneiter R. Wymann MP, et al. Nat Rev Mol Cell Biol. 2008 Feb;9(2):162-76. doi: 10.1038/nrm2335. Nat Rev Mol Cell Biol. 2008. PMID: 18216772 Free article. Review.
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy.
Tarantelli C, Gaudio E, Arribas AJ, Kwee I, Hillmann P, Rinaldi A, Cascione L, Spriano F, Bernasconi E, Guidetti F, Carrassa L, Pittau RB, Beaufils F, Ritschard R, Rageot D, Sele A, Dossena B, Rossi FM, Zucchetto A, Taborelli M, Gattei V, Rossi D, Stathis A, Stussi G, Broggini M, Wymann MP, Wicki A, Zucca E, Cmiljanovic V, Fabbro D, Bertoni F. Tarantelli C, et al. Among authors: wymann mp. Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24. Clin Cancer Res. 2018. PMID: 29066507 Free article.
A class of highly selective inhibitors bind to an active state of PI3Kγ.
Gangadhara G, Dahl G, Bohnacker T, Rae R, Gunnarsson J, Blaho S, Öster L, Lindmark H, Karabelas K, Pemberton N, Tyrchan C, Mogemark M, Wymann MP, Williams RL, Perry MWD, Papavoine T, Petersen J. Gangadhara G, et al. Among authors: wymann mp. Nat Chem Biol. 2019 Apr;15(4):348-357. doi: 10.1038/s41589-018-0215-0. Epub 2019 Feb 4. Nat Chem Biol. 2019. PMID: 30718815
The chemical biology of phosphoinositide 3-kinases.
Wymann MP, Schultz C. Wymann MP, et al. Chembiochem. 2012 Sep 24;13(14):2022-35. doi: 10.1002/cbic.201200089. Epub 2012 Sep 10. Chembiochem. 2012. PMID: 22965647 Review.
(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-amine (PQR530), a Potent, Orally Bioavailable, and Brain-Penetrable Dual Inhibitor of Class I PI3K and mTOR Kinase.
Rageot D, Bohnacker T, Keles E, McPhail JA, Hoffmann RM, Melone A, Borsari C, Sriramaratnam R, Sele AM, Beaufils F, Hebeisen P, Fabbro D, Hillmann P, Burke JE, Wymann MP. Rageot D, et al. Among authors: wymann mp. J Med Chem. 2019 Jul 11;62(13):6241-6261. doi: 10.1021/acs.jmedchem.9b00525. Epub 2019 Jun 20. J Med Chem. 2019. PMID: 31244112
108 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page